NovalGen announces two oral presentations at upcoming conferences
-Updated pre-clinical data for NVG-444, a novel FVIII mimetic bispecific antibody with our proprietary autoregulation platform technology in patients with haemophilia A to be presented at ISTH 2023 Congress-
- Updated pre-clinical data for NVG-222, a first in class half-life extended T Cell engager targeting ROR1-
London, United Kingdom, 9 June, 2023 – NovalGen Ltd (“NovalGen”), a biopharmaceutical company developing disruptive therapies, based on a proprietary autoregulation (AR) platform, today announces the presentation of preclinical data on this novel technology in two separate indications at the International Society on Thrombosis and Haemostasis Congress (ISTH), 24-28 June, 2023 in Toronto and the Immuno-Oncology Summit Boston 2023, 7-9 August, 2023 in Boston.
“We are delighted to be showcasing our proprietary platform, which has the potential to improve the safety profile and therapeutic index of a range of immunotherapies. Preclinical data with NVG-444 shows a reduction in thrombotic complications with a bispecific Factor VIII mimetic. These data will be presented in an oral presentation at ISTH. The AR platform is target agnostic as illustrated by its application to an extended half-life T cell engager (TCE) targeting ROR1, resulting in a dramatic reduction in toxicity, thus addressing the “Achilles heel” of TCEs allowing more patients to benefit from this off the shelf, T cell activating technology. The AR technology can be applied to a wide range of immunotherapies and heralds a new and exciting class of self-regulating drugs that respond to biological cues to avoid life-threatening toxicities,” said Professor Amit Nathwani, Founder and CEO of NovalGen.
Both abstracts will be delivered as oral presentations at the conferences.
Abstracts to be presented:
- Conference: ISTH 2023 Congress
Abstract Title: Thrombin-mediated autoregulation restores sensitivity to the coagulation feedback loop and reduces the risk of prothrombotic events associated with FVIII mimetic antibodies.
Abstract Presentation Number: OC 69.1
Session Title: Hemophilia – Novel therapies II
Session Date: Wednesday, 28 June, 2023
Presentation Time: 10:15 am - 10:30 am
Presenting Author: Vincent Muczynski
- Conference: Immuno-Oncology Summit Boston 2023
Abstract Title: NVG-222: A ROR1-Targeting T Cell Engager with Integral Autoregulating Capability Designed to Reduce the Risk of Serious Adverse Events Related to T Cell Activation
Session Title: Bispecific Antibodies for Cancer Immunotherapy: Overcoming Obstacles to Efficacy
Session Date: Tuesday, 8 August, 2023
Presentation Time: 8:05am – 8:35am
Presenting Author: David Granger
- Ends -
Further information
NovalGen Ltd.
Laura Stanisci-Brown
Tel.+44(0207) 139 8639
Email: l.stanisci-brown@novalgen.co.uk
About NovalGen
NovalGen is a privately held clinical stage immuno-oncology company developing breakthrough bispecific therapies that can safely harness the immune system to fight cancer, with the aim of creating life-saving new treatments for people with cancer. Alongside this, we are building out our autoregulation platform that can be applied to a range of therapeutic indications heralding a new era of self-regulating drugs.
Our dedicated team of experienced scientists, physicians and professionals are passionate about building a pipeline of disruptive and differentiated products tailored to the needs of the patient.
The company’s lead program, NVG-111, is an ROR1-targeting bispecific antibody T cell engager for the treatment of both hematologic malignancies and solid tumors using our breakthrough bispecific technology.